drugset / Trial / NCT05457530
Doravirine and Weight Gain in Antiretroviral Naive
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is determine whether different antiretroviral therapy (ART) changes the effects on body fat and predict the weight change in Black and Hispanic females.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-05-03
- Completion
- 2023-05-03
Outcome
Outcome not reported
Stopped (Enrollment): “Due to No/Low enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bictegravir | Small molecule | 50 mg | — |
| Comparator | DOR/3TC/TDF | Unknown | 300 mg | — |
| Comparator | Doravirine | Small molecule | 100 mg | — |
| Comparator | Lamivudine | Other / unclassified | 300 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |
| Subject | tenofovir alafenamide | Small molecule | 25 mg | — |